Opus Genetics (NASDAQ:IRD - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.
Several other equities analysts also recently issued reports on IRD. Craig Hallum assumed coverage on shares of Opus Genetics in a research note on Friday, April 11th. They issued a "buy" rating and a $6.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of Opus Genetics in a report on Friday. Finally, Jones Trading decreased their target price on Opus Genetics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.
Read Our Latest Analysis on Opus Genetics
Opus Genetics Price Performance
Shares of NASDAQ IRD traded down $0.00 during midday trading on Friday, hitting $0.94. 209,328 shares of the company's stock were exchanged, compared to its average volume of 525,599. The firm's fifty day simple moving average is $0.96 and its 200-day simple moving average is $1.02. The company has a market cap of $56.07 million, a PE ratio of -0.45 and a beta of -0.02. Opus Genetics has a twelve month low of $0.65 and a twelve month high of $1.75.
Opus Genetics (NASDAQ:IRD - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.02. Opus Genetics had a negative net margin of 429.42% and a negative return on equity of 283.28%. The business had revenue of $4.30 million during the quarter, compared to the consensus estimate of $4.00 million. Equities analysts anticipate that Opus Genetics will post -1.22 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of IRD. Virtu Financial LLC acquired a new stake in shares of Opus Genetics during the first quarter worth about $26,000. Apollon Wealth Management LLC acquired a new stake in Opus Genetics during the 1st quarter worth approximately $28,000. Comerica Bank acquired a new stake in Opus Genetics during the 1st quarter worth approximately $29,000. Kestra Private Wealth Services LLC purchased a new position in shares of Opus Genetics in the 1st quarter valued at approximately $47,000. Finally, Voss Capital LP acquired a new position in shares of Opus Genetics in the first quarter valued at approximately $147,000. 14.97% of the stock is owned by hedge funds and other institutional investors.
Opus Genetics Company Profile
(
Get Free Report)
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
See Also
Before you consider Opus Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opus Genetics wasn't on the list.
While Opus Genetics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
